A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Catalina Alamón und 16 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay. Hauptthemen laut MEDLINE: Brain Neoplasms, Boron Neutron Capture Therapy, Glioma, Glioblastoma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Institut Pasteur de Montevideo, Agencia Nacional de Investigaci?n e Innovaci?n, Universidad de la Rep?blica Uruguay.
Abstract (Originalsprache)
Glioblastoma (GBM), as the most central nervous system (CNS) intractable disease, has spoiled millions of lives due to its high mortality. Even though several efforts have been made, the existing treatments have had limited success. In this sense, we studied a lead compound, the boron-rich selective epidermal growth factor receptor (EGFR)-inhibitor hybrid 1, as a potential drug for GBM treatment. For this end, we analyzed the in vitro activity of hybrid 1 in a glioma/primary astrocytes coculture, studying cellular death types triggered by treatment with this compound and its cellular localizations. Additionally, hybrid 1 concentrated boron in glioma cells selectively and more effectively than the boron neutron capture therapy (BNCT)-clinical agent 10B-l-boronophenylalanine and thus displayed a better in vitro-BNCT effect. This encouraged us to analyze hybrid 1 in vivo. Therefore, immunosuppressed mice bearing U87 MG human GBM were treated with both 1 and 1 encapsulated in a modified liposome (recognized by brain-blood barrier peptide transporters), and we observed a potent in vivo per se antitumor activity (tumor size decrease and animal survival increase). These data demonstrate that 1 could be a promising new targeted therapy for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay.
- Laboratorio de Neurodegeneración, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay.
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay.
- Área Física, DETEMA, Facultad de Química, Universidad de la República, Montevideo 11800, Uruguay.
- Molecular Pharmacology, Faculty of Medicine, Technion Institute of Technology, Haifa 3200003, Israel.
- Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB, Bellaterra 08193, Spain.
ORCID-Profile: María Fernanda García, Ricardo Faccio, Francesc Teixidor, Clara Viñas, Hugo Cerecetto
Förderung
- Institut Pasteur de Montevideo
- Agencia Nacional de Investigaci?n e Innovaci?n
- Universidad de la Rep?blica Uruguay
- Comisi?n Sectorial de Investigaci?n Cient?fica
- FOCEM
Zitieren
APA
Alamón, C., Dávila, B., García, M. F., Nievas, S., Dagrosa, M. A., Thorp, S., Kovacs, M., Trias, E., Faccio, R., Gabay, M., Zeineh, N., Weizman, A., Teixidor, F., Viñas, C., Gavish, M., Cerecetto, H., & Couto, M. (2023). A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00152
Vancouver
Alamón C, Dávila B, García MF, Nievas S, Dagrosa MA, Thorp S, et al. A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00152
BibTeX
@article{Alamn2023,
author = {Alamón, Catalina and Dávila, Belén and García, María Fernanda and Nievas, Susana and Dagrosa, María Alejandra and Thorp, Silvia and Kovacs, Mariángeles and Trias, Emiliano and Faccio, Ricardo and Gabay, Martín and Zeineh, Nidal and Weizman, Abraham and Teixidor, Francesc and Viñas, Clara and Gavish, Moshe and Cerecetto, Hugo and Couto, Marcos},
title = {A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: In Vitro and in Vivo Exploration},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00152}
}
EUVIMED